Anti phospho sirt 1 ser47

Whole cell protein extracts were prepared according to Laemmli (1970 (link)). The primary antibodies used were: anti-ATM (1:500), anti-phospho-ATM Ser1981 (1:500), anti-p300 (1:500) (Abcam, Cambridge, UK), anti-GAPDH (1:50000) (Millipore, Darmstadt, Germany); anti-p21WAF1/Cip1 (1:500) (Sigma-Aldrich, St. Louis, USA); anti-p53 (1:500), (Santa Cruz Biotechnology, Santa Cruz, USA); anti-ATR (1:500), anti-phospho-ATR Ser428 (1:500), anti-phospho-p53 Ser15 (1:250), anti-acetyl-p53 Lys382 (1:200), anti-SIRT1 (1:250), anti-phospho-SIRT1 Ser47 (1:250), anti-p38 MAPK (1:500), anti-phospho-p38 MAPK Thr180/Tyr182 (1:500), anti-phospho-MAPKAPK-2 Thr334 (1:500), anti-AMPKα (1:500), anti-phospho-AMPKα Thr172 (1:1000), anti-ACC (1:500), anti-phospho-ACC Ser79 (1:1000), anti-mTOR (1:500), anti-phospho-mTOR Ser2448 (1:500), anti-phospho-S6 Ser235/236 (1:1000) (Cell Signaling Technology, Denvers, USA), anti-Rb (1:250) (NeoMarkers, Fremont, USA). The respective proteins were detected after incubation with one of the horseradish peroxidase-conjugated secondary antibodies (1:2000) (Dako, Glostrup, Denmark), using an ECL system (Thermo Scientific, Rockford, USA), according to the manufacturer’s instructions.

Whole cell protein of untreated and 24 h Rapha Myr^® extract (0.5–1.25–2.5% v/v)-treated cells were prepared according to Laemmli (1970) and submitted to Western blot analysis, performed according to Grabowska et al., 2016 [72 (link)]. The primary antibodies used were: anti-integrin α5 (1:1000) (Immunological Sciences, Rome, Italy), anti-GAPDH (1:50,000) (Millipore, Darmstadt, Germany), anti-Poly (ADP-ribose)polymerase (PARP, 1:1000) (BD Biosciences, San Jose, CA, USA), anti-γH2AX Ser139 (1:1000) (Abcam, Cambridge, UK), anti-p53 (1:500) (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-p21 (1:500) (Sigma-Aldrich, St. Louis, MO, USA), anti-phospho-p53 Ser15 (1:250), anti-sirt 1 (1:250), anti-phospho-sirt 1 Ser47 (1:250), anti-sirt 3 (1:500), anti-sirt 5 (1:500), anti-sirt 6 (1:1000) and anti-sirt 7 (1:250) (Cell Signalling Technology, Denvers, CO, USA). Each protein target was detected by using specific secondary horseradish peroxidase-conjugated antibodies (1:2000) (Dako, Glostrup, Denmark) and an ECL system (Thermo Scientific, Rockford, IL, USA). The expression level of proteins was measured by densitometric analysis using the software Image J and GAPDH was chosen as the reference protein.

Whole cell protein extracts were prepared according to Laemmli [56 (link)]. The primary antibodies used were: anti-ATM (1:500), anti-phospho-ATM Ser1981 (1:500) (Abcam, Cambridge, UK); anti-GAPDH (1:50000) (Millipore, Darmstadt, Germany); anti-p53 (1:500) (Santa Cruz Biotechnology, Santa Cruz, USA); anti-p21 (1:500) (Sigma-Aldrich, St. Louis, USA); anti-phospho-p53 Ser15 (1:250), anti-sirt 1 (1:250), anti-phospho-sirt 1 Ser47 (1:250), anti-sirt 3 (1:500), anti-sirt 5 (1:500), anti-sirt 6 (1:1000), anti-sirt 7 (1:250) anti-AMPKα (1:500), anti-phospho-AMPKα Thr172 (1:1000), anti-phospho-ACC Ser79 (1:1000) (Cell Signaling Technology, Denvers, USA). The respective proteins were detected after incubation with the horseradish peroxidase-conjugated secondary antibodies (1:2000) (Dako, Glostrup, Denmark), using an ECL system (Thermo Scientific, Rockford, USA, according to the manufacturer's instructions.